FBIOP — Stock Film
STOCK FILMSCENE 1/11FBIOP · $18.27
Stock Expert AI presents
FBIOP
Fortress Biotech, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Fortress Biotech, Inc. A quick introduction.

On the stock market since 2017, it operates in the world of health and science. It has 78 employees. Now — the numbers.

on the stock market since 2017
78 employees
$150.4M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $11 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 11%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
66%Qbrexza
Qbrexza 66%Accutane 34%
66% of all revenue comes from a single line: Qbrexza.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

What executives did with their own stock over the last 12 months:
10 buy0 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
89
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
46
weak

Clearly below the class average.

VALUATION
27
very weak

Clearly below the class average.

GROWTH
55
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
83
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
WEAK SPOTS
Growth has stalled4/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 31% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Strong cash, light debt

There is $79.4M in the vault; even if every debt were paid off, $5.1M would remain.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 10 buys and 0 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Pays a steady dividend

It pays out $2.34 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/3
Sales are shrinking

Over the last 3 years, sales fell about 6% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.

2
THE RISKS · 2/3
The price runs ahead of the earnings

Today’s price already includes part of tomorrow’s optimism. Report-card grade: 27/100.

3
THE RISKS · 3/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 46/100.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, FBIOP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: FBIOP is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film